Related Experiment Video

Updated: Feb 28, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K

Advances in Ebola virus vaccination

Elizabeth C Clarke1, Steven B Bradfute1

  • 1Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.

The Lancet. Infectious Diseases
|June 14, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.6K
Expression and Purification of Virus-like Particles for Vaccination06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
33.3K
Vaccinations01:51

Vaccinations

Overview
52.4K